Share

EORTC Melanoma Group Spring Meeting

Turin, Italy

The EORTC Melanoma Group Spring meeting will be held in Turin, Italy on 21-22 March 2024. It is only open to individual or site staff members of the group.

Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC Melanoma Group, and you have not received the registration link, please contact events@eortc.org.

LOCANDINA-21_22-03-24 (Save The Date)

AGENDA

 

 

21.03.24
Time slot
Topic / Title of presentation Speaker
12:30 – 13:15 Lunch
13.00 – 13.15 Opening cerimonia
Welcome and Introduction
Prof Mario Mandalà
Prof Simone Ribero
13.15 – 13:20 Introduction to the session of the ECI chairs Prof Francesca Maria Bosisio
13:20 – 13:55 Fertility preservation and pregnancy counseling in patients undergoing systemic therapy for melanoma Dr Alice Indini
13:55-14:25 Patients with T1a melanoma at Critical Structures: Association of Excison Margin Size With Local Recurrence and Survival Dr Ilaria mattavelli
14:25-14:55 The role of microRNA in cutaneous melanoma as diagnostic and prognostic biomarkers Dr Venturi
14:55-15:00  Closing remarks Prof Francesca Maria Bosisio
15.00-17.00 Pathology subgroup
15:00-15:05 Welcome Prof Rebecca Senetta Prof Daniela Massi
15:05-15:35 Stromal cues impact melanoma tropism Dr Amaya Viros
15:35-15:50 Spitz vs. Spitzoid / Meta vs. Deposit? Dr. Anna Szumera-Ciećkiewicz
15:50-16:05 Melanoma in Biella: consideration about one year’s experience Dr Alberto Pisacane
16:05-16:20 Genomics and transcriptomics elucidate the ICI response of an NF1-driven anorectal melanoma Dr Enrico Berrino
16:20-16:35 Sex-specific prognostic biomarkers in early-stage melanoma Dr Giovanna Chiorino
16:35-16.55 Lecture Prof Raymond Barnhill
16:55-17:00 Closing remarks Prof Rebecca Senetta
Prof Daniela Massi
17:00-19:00 Steering Committee Meeting
20:00-22:00 Dinner
Circolo dei lettori
Via Bogino 9

 

22.03.24
Time slot
Topic / Title of presentation Speaker
08.50-08.55
Opening Cerimonia
Prof Mario Mandalà
Prof Bastian Schilling
08.55-09.00
Lecture introduction
Prof Pietro Quaglino
09.00-09.30
Lecture: RESISTANCE TO TARGETED THERAPY AND IMMUNOTHERAPY  IN MELANOMA
Prof Dario Sangiolo
09.30-09:35
Early Career Investigators’ (ECI-M) Meeting – Welcome Prof Francesca Maria Bosisio
09:35-09:50
Real-world outcomes of adjuvant therapy in melanoma: the Turin experience at 4 years Dr Gabriele Roccuzzo
09:50-10:05
Adjuvant therapy for stage III melanoma: correlation of pathological and molecular characteristics with survival outcomes Dr Tagliatela Ida
10:05-10:20
LDH isoforms in stage III and stage IV melanoma: and underestimated prognostic biomarker Dr Laura Soumoy
10.20-10.50
Break
10.50 -11.05
Prediction of malignant potential of Ambiguous MELanocytic skin lesions based on whole genome copy number Analysis (AMELA) Dr Hanne Goris
11:05-11:20
Initial results of CAcTUS: A biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted and immune therapy in patients with advanced cutaneous melanoma
Dr Rebecca Lee
11:20-11:35
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma Dr Oliver Kennedy
11:35-11:50
Long-term efficacy of perioperative therapy in borderline resectable III B-D and IV melanoma Dr Anna M. Czarnecka
11:50-11:55
Concluding remarks Prof Francesca Maria Bosisio
11.55-12.00
Lecture introduction
Prof Mario Mandalà
12.00-12.30
Lecture: A brief history of an EORTC statistician
Dr Stefan Suciu
12.30-13.45
Lunch
14.00-14.50
New study proposals
Prof Paul Nathan
Prof Bastian Schilling
14.00-14.05 Introduction Prof Paul Nathan
14.05-14.25
Observational Trial of Sequencing Targeted Therapy and Immune-Checkpoint Inhibition in BRAF Mutant Metastatic Melanoma (liquidSWITCH)
Prof Christoffer Gebhardt
14.25-14.45
NeoMEL (Neoadjuvant immunotherapy in MELanoma) schema
Dr Brent O’Carrigan
14.45-14.50
Concluding remarks
Prof Paul Nathan
Prof Mario Mandalà
14.50-15.00
Break
15.00-15.45
Updates of EORTC clinical trials
Prof Bastian Schilling
Prof Mario Mandalà
15.00-15.15
1612-EBIN: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF-V600 mutation: an EORTC randomized phase II study
Prof Caroline Robert
15.15-15.30
1208-Minitub: Prospective registry on Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissections (CLND) or Nodal Observation
Prof Alexander van Akkooi
15.30-15.45
2022-ATOM: Adjuvant Tebentafusp (IMCgp100) versus observation in HLA-A*0201 positive patients following definitive treatment of high-risk uveal melanoma (UM): a randomized Phase III study.
Prof Paul Nathan
15.45-16.00
Meeting Closure 
Prof Pietro Quaglino
Prof Mario Mandalà

VENUE

NH Collection Torino Piazza Carlina
15 Piazza Carlo Emanuele II
10123 Turin
Italy

Booking accommodation in the meeting venue (NH Collection Torino Piazza Carlina) is possible through this link until 20 February 2024.

Alternative accommodation is possible in Hotel Victoria Torino by completing and returning this form to the hotel.

Next events

  • The 10+1 Santorini Conference

    Santorini

  • EACR Annual Congress 2024

    Rotterdam, Netherlands

  • Clinical Trial Statistics for Non-Statisticians

    Brussels, BE

  • EORTC Leukemia Group Spring Meeting 2024

    Madrid, ES

  • 24th Workshop on Methods in Clinical Cancer Research (MCCR)

    Sint Michielgestel, Netherlands